Proteinuria News and Research

RSS

Proteinuria, also sometimes referred to as albuminuria or urine albumin, is a health condition characterized by an abnormal concentration of protein in the urine.

Vasculitis damage swift, accumulating

Study findings reveal the significant burden of disease among patients with antineutrophil-cytoplasm antibody associated vasculitis, with many individuals showing irreversible damage shortly after diagnosis.

22 Nov 2013

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure.

11 Nov 2013

Studies highlight potential negative effects of soft drinks, sugar on kidney health

Two new studies highlight the potential negative effects that soft drinks and sugar can have on kidney health. Results of these studies will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.

11 Nov 2013

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.

28 Oct 2013

ASN strongly recommends all adults to undergo routine screening for chronic kidney disease

The American Society of Nephrology strongly recommends that all adults undergo routine screening for chronic kidney disease (CKD), the 8th leading cause of death in the U.S. This contradicts screening guidelines recently released by the American College of Physicians (ACP).

23 Oct 2013

Obesity suppresses important cellular process that prevents kidney cell damage

Obesity increases a chronic kidney disease patient's risk of developing kidney failure. Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

7 Oct 2013

Obesity suppresses important cellular process that prevents kidney cell damage

Obesity suppresses an important cellular process that prevents kidney cell damage, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that restoring the process could protect the kidney health of obese individuals.

4 Oct 2013

Pregnant rats fed with high-fat diet experience preeclampsia-like syndromes

Preeclampsia is a relatively common pregnancy disorder, characterized by primary hypertension and proteinuria. In patients with severe preeclampsia, eclampsia can develop, causing nervous system symptoms and signs.

9 Aug 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Preclinical study shows PLX cells may help reverse symptoms associated with preeclampsia

Could the answer to repairing the ailing placenta in preeclampsia lie within the stem cells of a healthy placenta? New promising evidence may lead scientists to answer that question.

17 May 2013

Study links grape seed and skin extracts with high-fat-diet-induced renal disease

New insight into grape seed extract as a therapeutic and preventative measure to fight obesity-induced kidney damage is presented in a new study. Grape seed and skin extract (GSSE) is known to contain powerful antioxidants.

1 Mar 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Dual renin angiotensin system blockade: too many cons

Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.

31 Jan 2013

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMROTM (mipomersen sodium) injection.

30 Jan 2013

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced new preclinical data on the efficacy of anti-galectin therapy on diabetic kidney disease.

23 Jan 2013

Proteinuria common in canine lymphoma

Approximately a quarter of dogs with lymphoma have proteinuria, a much greater proportion than seen in healthy dogs, indicate research results.

16 Jan 2013

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

Pharmalink AB, a Swedish specialty pharma company, today announces it has initiated a Phase IIb study with Nefecon (Nefigan) in patients with primary IgA nephropathy at risk of developing end-stage renal disease.

18 Dec 2012

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Blocking the receptor for proteins that constrict blood vessels reduces markers of heart-related problems in patients with chronic kidney disease (CKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

14 Dec 2012

Proteinuria News and Research

Further Reading

Vasculitis damage swift, accumulating

Treatment with rheumatoid arthritis drug saved transplanted kidney and achieved remission

Studies highlight potential negative effects of soft drinks, sugar on kidney health

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

ASN strongly recommends all adults to undergo routine screening for chronic kidney disease

Obesity suppresses important cellular process that prevents kidney cell damage

Obesity suppresses important cellular process that prevents kidney cell damage

Pregnant rats fed with high-fat diet experience preeclampsia-like syndromes

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Preclinical study shows PLX cells may help reverse symptoms associated with preeclampsia

Study links grape seed and skin extracts with high-fat-diet-induced renal disease

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Dual renin angiotensin system blockade: too many cons

FDA approves Genzyme’s KYNAMRO to treat homozygous familial hypercholesterolemia

Galectin Therapeutics' GR-MD-02 reverses diabetic nephropathy in preclinical study

Proteinuria common in canine lymphoma

Pharmalink commences Nefecon Phase IIb study in primary IgA nephropathy

ETA receptor antagonism reduces novel cardiovascular risk factors in patients with CKD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News